• Dosage of Telmimarksans in details
• Telmimarksans interactions
• Telmimarksans reviews

Dosage of Telmimarksans in details

Telmimarksans Dosage

Generic name: Telmimarksans 20mg

Dosage form: tablet

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

2.1  Hypertension

Dosage must be individualized. The usual starting dose of Telmimarksans tablets is 40 mg once a day. Blood pressure response is dose-related over the range of 20 to 80 mg.

Most of the antihypertensive effect is apparent within 2 weeks and maximal reduction is generally attained after 4 weeks. When additional blood pressure reduction beyond that achieved with 80 mg Telmimarksans is required, a diuretic may be added.

No initial dosage adjustment is necessary for elderly patients or patients with renal impairment, including those on hemodialysis. Patients on dialysis may develop orthostatic hypotension; their blood pressure should be closely monitored.

Telmimarksans tablets may be administered with other antihypertensive agents.

Telmimarksans tablets may be administered with or without food.

2.2  Cardiovascular Risk Reduction

The recommended dose of Telmimarksans tablets is 80 mg once a day and can be administered with or without food. It is not known whether doses lower than 80 mg of Telmimarksans are effective in reducing the risk of cardiovascular morbidity and mortality.

When initiating Telmimarksans therapy for cardiovascular risk reduction, monitoring of blood pressure is recommended, and if appropriate, adjustment of medications that lower blood pressure may be necessary.

More about Telmimarksans (Telmimarksans)

• Side Effects
• During Pregnancy or Breastfeeding
• Dosage Information
• Drug Images
• Drug Interactions
• Support Group
• Pricing & Coupons
• En Espanol
• 25 Reviews - Add your own review/rating
• Generic Availability

Consumer resources

• Telmimarksans
• Telmimarksans (Advanced Reading)

Professional resources

• Telmimarksans (AHFS Monograph)
• Telmimarksans (FDA)

Other formulations

• Telmimarksans HCT

Related treatment guides

• Cardiovascular Risk Reduction
• High Blood Pressure
• Prevention of Cardiovascular Disease

What other drugs will affect Telmimarksans?

Tell your doctor about all medicines you use, and those you start or stop using during your treatment with Telmimarksans, especially:

• digoxin;

• lithium;

• a diuretic or "water pill";

• NSAIDs (non-steroidal anti-inflammatory drugs)--aspirin, ibuprofen (Advil, Motrin), naproxen (Aleve), celecoxib, diclofenac, indomethacin, or meloxicam, and others; or

• ramipril or other blood pressure medicines.

This list is not complete. Other drugs may interact with Telmimarksans, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.

Telmimarksans interactions

Aliskiren: Do not co-administer aliskiren with Telmimarksans in patients with diabetes. Avoid use of aliskiren with Telmimarksans in patients with renal impairment (GFR < 60 mL/min).

Digoxin: When Telmimarksans was co-administered with digoxin, median increases in digoxin peak plasma concentration (49%) and in trough concentration (20%) were observed. Therefore, monitor digoxin levels when initiating, adjusting, and discontinuing Telmimarksans for the purpose of keeping the digoxin level within the therapeutic range.

Lithium: Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists including Telmimarksans. Therefore, monitor serum lithium levels during concomitant use.

Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including Telmimarksans, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving Telmimarksans and NSAID therapy.

The antihypertensive effect of angiotensin II receptor antagonists, including Telmimarksans may be attenuated by NSAIDs including selective COX-2 inhibitors.

Ramipril and Ramiprilat: Co-administration of Telmimarksans 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3-and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4-and 1.5-fold, respectively. In contrast, Cmax and AUC of Telmimarksans decrease by 31% and 16%, respectively. When co-administering Telmimarksans and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of Telmimarksans. Concomitant use of Telmimarksans and ramipril is not recommended.

Other Drugs: Co-administration of Telmimarksans did not result in a clinically significant interaction with acetaminophen, amlodipine, glyburide, simvastatin, hydrochlorothiazide, warfarin, or ibuprofen. Telmimarksans is not metabolized by the cytochrome P450 system and had no effects in vitro on cytochrome P450 enzymes, except for some inhibition of CYP2C19. Telmimarksans is not expected to interact with drugs that inhibit cytochrome P450 enzymes; it is also not expected to interact with drugs metabolized by cytochrome P450 enzymes, except for possible inhibition of the metabolism of drugs metabolized by CYP2C19.

References

1. DailyMed. "AMLODIPINE BESYLATE; TELMISARTAN: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
2. FDA/SPL Indexing Data. "U5SYW473RQ: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
3. MeSH. "Angiotensin II Type 1 Receptor Blockers". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Telmimarksans are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Telmimarksans. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name:  Email:  Spam protection:  < Type 29 here

Information checked by Dr. Sachin Kumar, MD Pharmacology